168. Early Tirofiban Infusion after Intravenous Thrombolysis for Stroke.
作者: Chunrong Tao.;Tianlong Liu.;Tao Cui.;Jie Liu.;Zongliang Li.;Youquan Ren.;Xingli Zhao.;Fuyou Xie.;Jianqiao Li.;Hao Wang.;Ling Huang.;Jianjun Li.;Jianshang Wen.;Jianzhong Zeng.;Junyong Zhu.;Zhide Li.;Dajun Li.;Xuefeng Hu.;Biao Huang.;Jing Wang.;Chi Zhang.;Bin Ye.;Yubao Hou.;Yanlin Gan.;Hong Sun.;Fei Guan.;Ya Shao.;Zongtao Liu.;Zehu Ou.;Shikai Fan.;Yao Wang.;Hongjiang Zhai.;Chunhua Ni.;Hao Wang.;Chenggang Zhang.;Yan Zhao.;Guoping Wang.;Yuyou Zhu.;Rui Li.;Jun Sun.;Haiying Hu.;Jiangping Cui.;Li Wang.;Chao Zhang.;Jianlong Song.;Xiaozhong Jing.;Anmo Wang.;Jinjing Wang.;Pengfei Xu.;Adnan I Qureshi.;Thanh N Nguyen.;Raul G Nogueira.;Jeffrey L Saver.;Wei Hu.; .
来源: N Engl J Med. 2025年
Intravenous thrombolysis remains a standard treatment for acute ischemic stroke within 4.5 hours after onset. Vascular reocclusion may occur after intravenous thrombolysis and may be preventable with an antiplatelet agent within the first 24 hours after thrombolysis. Tirofiban, a platelet glycoprotein IIb-IIIa receptor antagonist, has reduced macrovascular reocclusion in experimental models.
|